Patents by Inventor Ronald Yamamoto
Ronald Yamamoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11944703Abstract: An ocular medical injector is provided for drug delivery. A method includes inserting a puncture member of the medical injector into the eye until the puncture member reaches the suprachoroidal space (SCS). The puncture member defines a lumen therethrough. With the puncture member disposed within the SCS, a flexible cannula is advanced distally through the lumen of the puncture member, beyond the distal end portion of the puncture member and along the SCS towards a posterior region of the eye. The flexible cannula has an atraumatic distal tip and defines a lumen therethrough. With the distal tip of the flexible cannula disposed within the SCS beyond a distal end portion of the puncture member, a therapeutic substance is administered to the SCS.Type: GrantFiled: August 3, 2023Date of Patent: April 2, 2024Assignee: Clearside Biomedical, Inc.Inventors: Ronald Yamamoto, Stanley R. Conston, David Sierra
-
Publication number: 20230372235Abstract: An ocular medical injector is provided for drug delivery. A method includes inserting a puncture member of the medical injector into the eye until the puncture member reaches the SCS. The puncture member defines a lumen therethrough. With the puncture member disposed within the SCS, a flexible cannula is advanced distally through the lumen of the puncture member, beyond the distal end portion of the puncture member and along the SCS towards a posterior region of the eye. The flexible cannula has an atraumatic distal tip and defines a lumen therethrough. With the distal tip of the flexible cannula disposed within the SCS beyond a distal end portion of the puncture member, a therapeutic substance is administered to the SCS.Type: ApplicationFiled: August 3, 2023Publication date: November 23, 2023Inventors: Ronald YAMAMOTO, Stanley R. CONSTON, David SIERRA
-
Patent number: 11752101Abstract: An ocular medical injector is provided for drug delivery. A method includes inserting a puncture member of the medical injector into the eye until the puncture member reaches the SCS. The puncture member defines a lumen therethrough. With the puncture member disposed within the SCS, a flexible cannula is advanced distally through the lumen of the puncture member, beyond the distal end portion of the puncture member and along the SCS towards a posterior region of the eye. The flexible cannula has an atraumatic distal tip and defines a lumen therethrough. With the distal tip of the flexible cannula disposed within the SCS beyond a distal end portion of the puncture member, a therapeutic substance is administered to the SCS.Type: GrantFiled: April 1, 2022Date of Patent: September 12, 2023Assignee: CLEARSIDE BIOMEDICAL, INC.Inventors: Ronald Yamamoto, Stanley R. Conston, David Sierra
-
Patent number: 11622884Abstract: The present invention provides a cannulation device for administering an active agent containing composition to the suprachoroidal space or supraciliary space. The invention provides methods of treatment of an ocular disease or condition accordingly. The invention also provides compositions for use in a method of treatment of an ocular disease or condition for delivery into the suprachoroidal space or supraciliary space.Type: GrantFiled: March 16, 2017Date of Patent: April 11, 2023Assignee: Oxular LimitedInventors: Robert Steven Bley, Stanley R. Conston, Ronald Yamamoto
-
Publication number: 20220409560Abstract: The present invention provides a method for the treatment of retinoblastoma comprising administering a composition comprising a therapeutically active agent to a subject in need thereof by injection of the composition into the vitreous cavity, suprachoroidal space, supraciliary space or sub-Tenon's space of the eye adjacent to a retinoblastoma tumour. The invention also provides a composition comprising at least one therapeutically active agent selected from the group consisting of a Bcl-2 inhibitor or a topoisomerase inhibitor for use in the treatment of retinoblastoma, wherein the composition is for administration into the vitreous cavity, suprachoroidal space, sub-Tenon's space, or supraciliary space adjacent to a retinoblastoma tumour in an eye. Also provided is a kit comprising a Bcl-2 inhibitor and a topoisomerase inhibitor for use in the treatment of retinoblastoma, wherein the Bcl-2 inhibitor and the topoisomerase inhibitor are for separate, simultaneous or sequential administration.Type: ApplicationFiled: November 27, 2020Publication date: December 29, 2022Inventors: Peter Charlton, Afsoon Fallahi, Tien Nguyen, Ronald Yamamoto
-
Publication number: 20220347014Abstract: An ocular medical injector is provided for drug delivery. A method includes inserting a puncture member of the medical injector into the eye until the puncture member reaches the SCS. The puncture member defines a lumen therethrough. With the puncture member disposed within the SCS, a flexible cannula is advanced distally through the lumen of the puncture member, beyond the distal end portion of the puncture member and along the SCS towards a posterior region of the eye. The flexible cannula has an atraumatic distal tip and defines a lumen therethrough. With the distal tip of the flexible cannula disposed within the SCS beyond a distal end portion of the puncture member, a therapeutic substance is administered to the SCS.Type: ApplicationFiled: April 1, 2022Publication date: November 3, 2022Applicant: CLEARSIDE BIOMEDICAL, INC.Inventors: Ronald YAMAMOTO, Stanley R. CONSTON, David SIERRA
-
Publication number: 20220062040Abstract: The present invention provides devices to access the suprachoroidal space or sub-retinal space in an eye via a minimally invasive transconjunctival approach. The devices may also be used after a partial dissection, for example after dissection of the outer scleral layer of the eye, and using the device within the dissection to access the suprachoroidal space or the sub-retinal space.Type: ApplicationFiled: March 22, 2021Publication date: March 3, 2022Inventors: Amy Lee HAMMACK, Stanley R. CONSTON, Ronald YAMAMOTO
-
Publication number: 20220062041Abstract: The present invention provides devices to access the suprachoroidal space or sub-retinal space in an eye via a minimally invasive transconjunctival approach. The devices may also be used after a partial dissection, for example after dissection of the outer scleral layer of the eye, and using the device within the dissection to access the suprachoroidal space or the sub-retinal space.Type: ApplicationFiled: November 10, 2021Publication date: March 3, 2022Applicant: CLEARSIDE BIOMEDICAL, INC.Inventors: Amy Lee HAMMACK, Stanley R. CONSTON, Ronald YAMAMOTO
-
Publication number: 20210212940Abstract: Drug formulations, devices and methods are provided to deliver biologically active substances to the eye. The formulations are delivered into scleral tissues adjacent to or into the suprachoroidal space without damage to the underlying choroid. One class of formulations is provided wherein the formulation is localized in the suprachoroidal space near the region into which it is administered. Another class of formulations is provided wherein the formulation can migrate to another region of the suprachoroidal space, thus allowing an injection in the anterior region of the eye in order to treat the posterior region.Type: ApplicationFiled: March 30, 2021Publication date: July 15, 2021Applicant: CLEARSIDE BIOMEDICAL, INC.Inventors: Ronald YAMAMOTO, Stanley R. CONSTON, David SIERRA
-
Publication number: 20210169689Abstract: The present invention provides a delivery device for administration of active agent (12) containing compositions into the suprachoroidal space or supraciliary space. The invention provides methods of treatment of an ocular disease or condition accordingly. The invention also provides active agent containing compositions for delivery into the suprachoroidal space or supraciliary space.Type: ApplicationFiled: March 16, 2017Publication date: June 10, 2021Inventors: Robert Steven Bley, Stanley R. Conston, Tien T. Nguyen, Ronald Yamamoto, Brad Michael Howarth, Adam Jonathan Frederick Stops, Ricky Barnett
-
Patent number: 10952894Abstract: The present invention provides devices to access the suprachoroidal space or sub-retinal space in an eye via a minimally invasive transconjunctival approach. The devices may also be used after a partial dissection, for example after dissection of the outer scleral layer of the eye, and using the device within the dissection to access the suprachoroidal space or the sub-retinal space.Type: GrantFiled: January 16, 2018Date of Patent: March 23, 2021Assignee: CLEARSIDE BIOMEDICAL, INC.Inventors: Amy Lee Hammack, Stanley R. Conston, Ronald Yamamoto
-
Publication number: 20200390692Abstract: Drug formulations, devices and methods are provided to deliver biologically active substances to the eye. The formulations are delivered into scleral tissues adjacent to or into the suprachoroidal space without damage to the underlying choroid. One class of formulations is provided wherein the formulation is localized in the suprachoroidal space near the region into which it is administered. Another class of formulations is provided wherein the formulation can migrate to another region of the suprachoroidal space, thus allowing an injection in the anterior region of the eye in order to treat the posterior region.Type: ApplicationFiled: January 13, 2020Publication date: December 17, 2020Applicant: CLEARSIDE BIOMEDICAL, INC.Inventors: Ronald YAMAMOTO, Stanley R. CONSTON, David SIERRA
-
Publication number: 20200330269Abstract: The present invention provides a cannulation device for administering an active agent containing composition to the suprachoroidal space or supraciliary space. The invention provides methods of treatment of an ocular disease or condition accordingly. The invention also provides compositions for use in a method of treatment of an ocular disease or condition for delivery into the suprachoroidal space or supraciliary space.Type: ApplicationFiled: March 16, 2017Publication date: October 22, 2020Inventors: Robert Steven BLEY, Stanley R. CONSTON, Ronald YAMAMOTO
-
Publication number: 20200121504Abstract: An implant is placed within Schlemm's canal of the eye and provides tension to the trabecular meshwork. The tension is continuous and increases the aqueous outflow without the necessity of administering cholinergic drugs to treat glaucoma.Type: ApplicationFiled: December 23, 2019Publication date: April 23, 2020Applicant: iScience lnterventional CorporationInventors: Robert Stegmann, Stanley R. Conston, David J. Kupiecki, John McKenzie, Candice D. Pinson, Ronald Yamamoto
-
Publication number: 20190000669Abstract: The present invention provides devices to access the suprachoroidal space or sub-retinal space in an eye via a minimally invasive transconjunctival approach. The devices may also be used after a partial dissection, for example after dissection of the outer scleral layer of the eye, and using the device within the dissection to access the suprachoroidal space or the sub-retinal space.Type: ApplicationFiled: January 16, 2018Publication date: January 3, 2019Applicant: Clearside Biomedical, Inc.Inventors: Amy Lee HAMMACK, Stanley R. CONSTON, Ronald YAMAMOTO
-
Publication number: 20170340560Abstract: Drug formulations, devices and methods are provided to deliver biologically active substances to the eye. The formulations are delivered into scleral tissues adjacent to or into the suprachoroidal space without damage to the underlying choroid. One class of formulations is provided wherein the formulation is localized in the suprachoroidal space near the region into which it is administered. Another class of formulations is provided wherein the formulation can migrate to another region of the suprachoroidal space, thus allowing an injection in the anterior region of the eye in order to treat the posterior region.Type: ApplicationFiled: January 4, 2017Publication date: November 30, 2017Inventors: Ronald YAMAMOTO, Stanley R. CONSTON, David SIERRA
-
Publication number: 20170290702Abstract: Drug formulations, devices and methods are provided to deliver biologically active substances to the eye. The formulations are delivered into scleral tissues adjacent to or into the suprachoroidal space without damage to the underlying choroid. One class of formulations is provided wherein the formulation is localized in the suprachoroidal space near the region into which it is administered. Another class of formulations is provided wherein the formulation can migrate to another region of the suprachoroidal space, thus allowing an injection in the anterior region of the eye in order to treat the posterior region.Type: ApplicationFiled: November 22, 2016Publication date: October 12, 2017Inventors: Ronald YAMAMOTO, Stanley R. CONSTON, David SIERRA
-
Patent number: 9561247Abstract: The present invention provides compositions and methods useful in the treatment of wounds, particularly in reducing or preventing scar formation, particularly hypertrophic scar or keloid formation. The invention thus further provides methods of treatment, including methods useful in hypertrophic scar or keloid revision as well as prophylactic, scar inhibiting methods.Type: GrantFiled: November 1, 2012Date of Patent: February 7, 2017Assignee: TIF Management, LLCInventors: Tien Nguyen, Kathleen Prudhomme, Ronald Yamamoto, Adam G. Lowe, Andrew Michael Green
-
Publication number: 20160193080Abstract: The present invention provides devices to access the suprachoroidal space or sub-retinal space in an eye via a minimally invasive transconjunctival approach. The devices may also be used after a partial dissection, for example after dissection of the outer scleral layer of the eye, and using the device within the dissection to access the suprachoroidal space or the sub-retinal space.Type: ApplicationFiled: August 7, 2015Publication date: July 7, 2016Applicant: CLEARSIDE BIOMEDICAL, INC.Inventors: Amy Lee HAMMACK, Stanley R. CONSTON, Ronald YAMAMOTO
-
Publication number: 20150265434Abstract: A flexible distal cup for use as part of a modular prosthetic socket for a residual limb may have a substantially closed distal end, an open proximal end, an inner surface and an outer surface. The flexible distal cup is configured to reside within an outer support structure of the prosthetic socket and to receive a distal portion of the residual limb. In some embodiments, the flexible distal cup may be made of a composite polymer composition, including an ethylene-vinyl acetate (EVA) copolymer and polycaprolactone (PCL). The EVA copolymer may be between about 45% and about 55% of the composite polymer composition by weight, the vinyl acetate of the EVA copolymer may be less than about 25% of the EVA copolymer by weight, and the PCL may be between about 45% and about 55% of the composite polymer composition by weight.Type: ApplicationFiled: March 19, 2015Publication date: September 24, 2015Inventors: Garrett Ray HURLEY, Jesse Robert WILLIAMS, Stanley R. CONSTON, Ronald YAMAMOTO